Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
Jade Biosciences (NASDAQ: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference from June 3-5, 2025, in New York. CEO Tom Frohlich will deliver a company presentation on June 4 at 4:55-5:25 p.m. ET. The management team will also conduct investor meetings during the event.
The presentation will be accessible to investors and the public through the Investors and Media section of JadeBiosciences.com, with the recording remaining available for 90 days afterward.
Jade Biosciences (NASDAQ: JBIO), un'azienda biotecnologica specializzata in terapie per malattie autoimmuni, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference, che si terrà dal 3 al 5 giugno 2025 a New York. Il CEO Tom Frohlich terrà una presentazione aziendale il 4 giugno dalle 16:55 alle 17:25 ET. Il team di gestione parteciperà inoltre a incontri con investitori durante l'evento.
La presentazione sarà accessibile a investitori e pubblico tramite la sezione Investors and Media di JadeBiosciences.com, e la registrazione resterà disponibile per 90 giorni successivi.
Jade Biosciences (NASDAQ: JBIO), una empresa biotecnológica especializada en terapias para enfermedades autoinmunes, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference, que se llevará a cabo del 3 al 5 de junio de 2025 en Nueva York. El CEO Tom Frohlich realizará una presentación de la empresa el 4 de junio de 4:55 a 5:25 p.m. ET. El equipo directivo también llevará a cabo reuniones con inversores durante el evento.
La presentación estará disponible para inversores y público a través de la sección Investors and Media en JadeBiosciences.com, y la grabación permanecerá accesible durante 90 días después del evento.
Jade Biosciences (NASDAQ: JBIO)는 자가면역 질환 치료제에 특화된 생명공학 회사로, 2025년 6월 3일부터 5일까지 뉴욕에서 열리는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. CEO 톰 프로흘리히는 6월 4일 오후 4시 55분부터 5시 25분(동부시간)까지 회사 발표를 진행할 예정입니다. 경영진 팀은 행사 기간 동안 투자자 미팅도 진행할 예정입니다.
발표는 투자자 및 일반 대중이 JadeBiosciences.com의 Investors and Media 섹션을 통해 시청할 수 있으며, 녹화 영상은 행사 후 90일간 제공됩니다.
Jade Biosciences (NASDAQ : JBIO), une société de biotechnologie spécialisée dans les thérapies des maladies auto-immunes, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference qui se tiendra du 3 au 5 juin 2025 à New York. Le PDG Tom Frohlich présentera l’entreprise le 4 juin de 16h55 à 17h25 (heure de l’Est). L’équipe de direction tiendra également des réunions avec des investisseurs pendant l’événement.
La présentation sera accessible aux investisseurs et au public via la section Investors and Media du site JadeBiosciences.com, et l’enregistrement restera disponible pendant 90 jours après la conférence.
Jade Biosciences (NASDAQ: JBIO), ein Biotechnologieunternehmen, das sich auf Therapien für Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an der kommenden Jefferies Global Healthcare Conference vom 3. bis 5. Juni 2025 in New York angekündigt. CEO Tom Frohlich wird am 4. Juni von 16:55 bis 17:25 Uhr ET eine Unternehmenspräsentation halten. Das Managementteam wird während der Veranstaltung auch Investorengespräche führen.
Die Präsentation wird Investoren und der Öffentlichkeit über den Bereich Investors and Media auf JadeBiosciences.com zugänglich sein, und die Aufzeichnung wird für 90 Tage danach verfügbar bleiben.
- None.
- None.
SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York.
Tom Frohlich, Chief Executive Officer of Jade, will deliver a company presentation on Wednesday, June 4 at 4:55-5:25 p.m. ET. Members of the management team will also host investor meetings during the conference.
Investors and the general public are invited to listen to the session by visiting the Investors and Media page on JadeBiosciences.com. An archived edition will be available following its conclusion for 90 days.
About Jade Biosciences, Inc.
Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE-001, targets the cytokine APRIL for immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade’s pipeline also includes two undisclosed antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Jade Biosciences Contacts
Media Contact
Priyanka Shah
Media@JadeBiosciences.com
908-447-6134
Investor Contact
IR@JadeBiosciences.com
FAQ
When is Jade Biosciences (JBIO) presenting at the 2025 Jefferies Healthcare Conference?
Who will be presenting for Jade Biosciences at the 2025 Jefferies Conference?
How can investors access Jade Biosciences' (JBIO) Jefferies Conference presentation?
What is Jade Biosciences' (JBIO) main business focus?
